Human Papillomavirus (HPV)-Associated Cancers

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Infectious Agents and Cancer".

Deadline for manuscript submissions: 30 June 2025 | Viewed by 405

Special Issue Editor


E-Mail Website
Guest Editor
Department of Microbiology and Immunology, The University of Western Ontario, London, ON N6A 3K7, Canada.
Interests: HPV; tumor virology; cancer immunology; extracellular vesicles

Special Issue Information

Dear Colleagues,

In ancient Roman and Greek texts, lesions that are similar to present-day genital warts were described, providing the earliest evidence of infections by the human papillomavirus (HPV). At the start of the 20th century, pioneering experiments demonstrated the contagious nature of warts and their viral origins. Anecdotal reports describing the spontaneous conversion of genital warts into squamous cell carcinomas ushered in an era of clinical research that aimed to establish an association between HPV infection and cancer. Ground-breaking research in the 1980s definitively identified two HPV genotypes, HPV type 16 (HPV16) and HPV type 18 (HPV18), as the causative agents of cervical cancer. Today, it is well established that infection with certain HPV types can give rise to not only cervical cancers, but also vaginal, vulvar, anal, penile, and head and neck cancers.

After a century from those initial experiments, HPVs are some of the most studied viruses in the world due to their sexual mode of transmission and their collective role in causing an estimated 4.1% of the global burden of cancer. Importantly, despite the availability of effective vaccines, some HPV-associated cancers are amongst the fastest rising cancers in certain geographical regions.

This Special Issue will focus on cancers associated with HPV infections, and we welcome authors to submit original research or comprehensive reviews that highlight the current research landscape on HPV-associated cancers that will advance our current understanding of this potent biological carcinogen.

Dr. Steven F. Gameiro
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • anal cancer
  • cervical cancer
  • head and neck cancers
  • oropharyngeal cancer
  • penile cancer
  • vaginal cancer
  • vulvar cancer
  • HPV
  • human papillomavirus

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

21 pages, 2324 KiB  
Review
Human Papillomaviruses and Malignant Neoplasms of the Female Upper Reproductive Tract: A Comprehensive Review of the Literature
by Charalampos Karachalios, Ilias Liapis, Stamatios Petousis, Emmanouela-Aliki Almperi, Chrysoula Margioula-Siarkou, Georgia Margioula-Siarkou, Stefanos Flindris, Evangelos Karamitrousis and Konstantinos Dinas
Cancers 2025, 17(12), 1995; https://doi.org/10.3390/cancers17121995 - 15 Jun 2025
Viewed by 114
Abstract
Malignancies of the female upper reproductive tract, especially endometrial and ovarian cancers, generate a significant burden for women worldwide. The possible etiopathogenetic role of chronic human papillomavirus (HPV) infection in the carcinogenesis of the female upper genital tract is neither clearly established not [...] Read more.
Malignancies of the female upper reproductive tract, especially endometrial and ovarian cancers, generate a significant burden for women worldwide. The possible etiopathogenetic role of chronic human papillomavirus (HPV) infection in the carcinogenesis of the female upper genital tract is neither clearly established not completely understood. Therefore, we performed a literature review, using the PubMed and SCOPUS electronic databases, of the prevalence of HPV DNA in endometrial, primary fallopian tube, ovarian, and primary peritoneal cancers, as well as uterine sarcomas. The present investigation covered 35 studies from different countries on various continents. Overall, the prevalence of HPV was approximately 15% in all the above cancers. HPV DNA was isolated from 11%, 0%, 0%, and 14% of endometrial carcinomas, uterine sarcomas, primary fallopian tube cancers, and ovarian malignant neoplasms, respectively. No relevant studies on primary peritoneal cancers were retrieved. The predominant HPV strain from tumors of the upper female reproductive tract, regardless of the tumor site, was HPV-16, followed by HPV-18. The HPV DNA identified was exclusively from subtypes HPV-6, HPV-11, HPV-16, HPV-18, and HPV-33, which are responsible for the development of not only cervical cancer, but also condylomata acuminata. The findings of the present review indicate that HPV vaccination might prove to be a useful strategy in the prevention of HPV-related carcinomas of the upper genital tract in women. Full article
(This article belongs to the Special Issue Human Papillomavirus (HPV)-Associated Cancers)
Show Figures

Figure 1

Back to TopTop